18800-26-5

Basic information

• Product Name: 1-(2-BROMOETHOXY)-2-CHLOROBENZENE
• Synonyms: ASISCHEM Z95337;1-(2-BROMOETHOXY)-2-CHLOROBENZENE;AKOS BC-2657;2-Chlorophenoxyethylbromide;1-(2-Bromoethoxy)-2-chlorobenzene,98%;1-(2-BroMoethoxy)-2-chlorobenzene, 98% 25GR
• CAS NO: 18800-26-5
• Molecular Formula: C₈H₈BrClO
• Molecular Weight: 235.51
• Mol File: 18800-26-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 140-142 °C (15 mmHg)
• Flash Point: 150 °C
• Appearance: Clear slightly yellow liquid
• Density: 1.518 g/cm³
• Vapor Pressure: 0.00889mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-2-CHLOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-2-CHLOROBENZENE(18800-26-5)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-2-CHLOROBENZENE(18800-26-5)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-20/22
• Safety Statements: 36/37/39-26
• Hazardous Substances Data: 18800-26-5(Hazardous Substances Data)

Usage

Chemical Properties

Clear slightly yellow liquid

InChI:InChI=1/C8H8BrClO/c9-5-6-11-8-4-2-1-3-7(8)10/h1-4H,5-6H2

Upstream product

• 95-57-8 2-monochlorophenol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 111354-75-7 ethyl-[2-(2-chloro-phenoxy)-ethyl]-dimethyl-ammonium; bromide 
• 29811-93-6 [2-(2-chloro-phenoxy)-ethyl]-heptyl-dimethyl-ammonium; bromide 
• 29811-94-7 [2-(2-chloro-phenoxy)-ethyl]-dimethyl-octyl-ammonium; bromide 
• 29811-96-9 [2-(2-chloro-phenoxy)-ethyl]-dodecyl-dimethyl-ammonium; bromide 
• 109725-92-0 [2-(2-chloro-phenoxy)-ethyl]-dimethyl-propyl-ammonium; bromide 
• 132493-60-8 butyl-[2-(2-chloro-phenoxy)-ethyl]-dimethyl-ammonium; bromide 
• 132886-37-4 [2-(2-chloro-phenoxy)-ethyl]-dimethyl-pentyl-ammonium; bromide 
• 132753-65-2 [2-(2-chloro-phenoxy)-ethyl]-hexyl-dimethyl-ammonium; bromide 
• 29811-95-8 [2-(2-chloro-phenoxy)-ethyl]-decyl-dimethyl-ammonium; bromide 
• 30035-86-0 [2-(2-chloro-phenoxy)-ethyl]-dimethyl-tetradecyl-ammonium; bromide 
• 29811-97-0 [2-(2-chloro-phenoxy)-ethyl]-hexadecyl-dimethyl-ammonium; bromide 
• 496-16-2 2.3-dihydrobenzofuran 
• 38380-93-7 (2-chloro-phenyl)-vinyl ether 
• 70289-29-1 [2-(2-chloro-phenoxy)-ethyl]-methyl-amine 

Relevant articles and documents

Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybrids

Abstract: Antimicrobial resistance has become a significant threat to global public health, thus precipitating an exigent need for new drugs with improved therapeutic efficacy. In this regard, molecular hybridization is deemed as a viable strategy to afford multi-target-based drug candidates. Herein, we report a library of quinoline—1H-1,2,3-triazole molecular hybrids synthesized via copper(I)-catalyzed azide-alkyne [3 + 2] dipolar cycloaddition reaction (CuAAC). Antimicrobial evaluation identified compound 16 as the most active hybrid in the library with a broad-spectrum antibacterial activity at an MIC80 value of 75.39?μM against methicillin-resistant S. aureus, E. coli, A. baumannii, and multidrug-resistant K. pneumoniae. The compound also showed interesting antifungal profile against C. albicans and C. neoformans at an MIC80 value of 37.69 and 2.36?μM, respectively, superior to fluconazole. In vitro toxicity profiling revealed non-hemolytic activity against human red blood cells (hRBC) but partial cytotoxicity to human embryonic kidney cells (HEK293). Additionally, in silico studies predicted excellent drug-like properties and the importance of triazole ring in stabilizing the complexation with target proteins. Overall, these results present compound 16 as a promising scaffold on which other molecules can be modeled to deliver new antimicrobial agents with improved potency. Graphic abstract: [Figure not available: see fulltext.].

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.